financetom
Business
financetom
/
Business
/
Myriad Genetics, GSK Partner to Expand Access to HRD Diagnostic Testing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Myriad Genetics, GSK Partner to Expand Access to HRD Diagnostic Testing
Jun 11, 2024 6:33 AM

09:04 AM EDT, 06/11/2024 (MT Newswires) -- Myriad Genetics ( MYGN ) said Tuesday it has partnered with GSK (GSK) to support access to homologous recombination deficiency diagnostic testing for patients with high-grade serous ovarian cancer.

A sponsored testing plan utilizing Myriad's MyChoice HRD Plus and MyChoice CDx Plus Tests is now available in Argentina, Brazil, Chile, Colombia, Egypt, Netherlands, Saudi Arabia, Singapore, and the United Arab Emirates, the company said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved